Mitochondrial DNA (mtDNA) mutations cause inherited diseases and are implicated in the pathogenesis of common lateonset disorders, but how they arise is not clear 1,2
. Here we show that mtDNA mutations are present in primordial germ cells (PGCs) within healthy female human embryos. Isolated PGCs have a profound reduction in mtDNA content, with discrete mitochondria containing ~5 mtDNA molecules. Singlecell deep mtDNA sequencing of in vivo human female PGCs showed rare variants reaching higher heteroplasmy levels in late PGCs, consistent with the observed genetic bottleneck. We also saw the signature of selection against non-synonymous protein-coding, tRNA gene and D-loop variants, concomitant with a progressive upregulation of genes involving mtDNA replication and transcription, and linked to a transition from glycolytic to oxidative metabolism. The associated metabolic shift would expose deleterious mutations to selection during early germ cell development, preventing the relentless accumulation of mtDNA mutations in the human population predicted by Muller's ratchet. Mutations escaping this mechanism will show shifts in heteroplasmy levels within one human generation, explaining the extreme phenotypic variation seen in human pedigrees with inherited mtDNA disorders.
The 16.5-kilobase human mitochondrial genome (mtDNA) encodes 37 genes essential for the synthesis of 13 polypeptide subunits of the respiratory chain, the final common pathway of oxidative metabolism 1 . In humans, mtDNA is inherited exclusively down the maternal line. Diploid cells typically contain 1-10,000 mtDNA molecules partitioned between a network of fusing and budding mitochondria. Exposed to a potent source of oxygen free radicals and lacking protective histone proteins, mtDNA is particularly vulnerable to mutation, creating a mixed population of wild-type and mutated mtDNA within a cell (heteroplasmy) 2 . MtDNA mutations accumulate in non-dividing (post mitotic) cells during life, with high levels observed in late-onset human disorders including Alzheimer's disease and Parkinson's disease. Although the overall tissue mutation burden is low, very high levels within single cells lead to bioenergetic failure and ultimately cause cell death 1 . These findings raise the possibility that mtDNA mutations contribute to the pathogenesis of several common human diseases, and also play a part in the ageing process itself 3 , but the origin of these mutations has not been clear. Age-associated mtDNA mutations were assumed to arise in somatic tissues during life, but deep sequencing of maternal relatives raised the possibility that low-level mtDNA heteroplasmic point mutations are inherited down the maternal line 4 . To determine whether this is the case, we developed methods to isolate pure primordial germ cells (PGCs) from first trimester karyotypically normal human female embryos (Fig. 1) . Anatomical regions containing migrating PGCs were dissected from fresh 4-week embryos, and genital ridges were isolated from 5-8-week embryos. Singlecell suspensions were then labelled with fluorochrome-conjugated antibodies against putative human germ cell surface markers, and sorted using fluorescence-activated cell sorting (FACS). Tissue non-specific alkaline phosphatase (TNAP) histochemistry 5 , VASA immunocytochemistry 6 (Supplementary Fig. 1 ) and germ-cell-specific transcripts (Supplementary Figs. 1 and 2) 7 were used to determine the proportion of PGCs after FACS sorting at appropriate developmental stages. Highly purified (> 97%) PGCs were isolated in 4-week (Carnegie stage, CS12) embryos using a combination of TNAP, stage-specific embryonic antigen 4 (SSEA4) and the PGCassociated cell-surface marker CD38; and for weeks 5-8 (CS16/17-CS20/21), we used TNAP and c-KIT antibodies (Fig. 1b) .
After cell lysis, mtDNA was amplified in overlapping 2-kilobase fragments to minimize potential contamination from nuclearencoded mitochondrial insertions (NumtS), before > 5,000-fold depth re-sequencing. NumtS contamination was further minimized by filtering-out all variants with a minor allele frequency (MAF) < 1%. Sequencing of a cloned mtDNA template showed no variants present at ≥ 1% MAF ( Supplementary Fig. 3 ). However, we observed mtDNA
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NATuRe Cell BIoloGy single-nucleotide variants at > 1% heteroplasmy in PGCs isolated from all 12 embryos studied (Fig. 2a) , which did not map to known human NumtS 8 . This shows that low-level mtDNA heteroplasmy is present within the female germ line in healthy humans. The variants were predominantly nucleotide transitions, which are less prone to in vitro sequencing error and less likely to be due to oxidative damage 9 , and are consistent with errors during in vivo DNA synthesis by mtDNA polymerase ϒ or the deamination of cytidine and adenosine 10 .
We also observed a change in the mutation spectrum from CS12 to CS20/21 (Fig. 2a) . For protein-coding genes, there was a decrease in the proportion of non-synonymous variants (non-synonymous/ synonymous ratio, P = 0.02) and a corresponding change in the codon bias (Fig. 2b,c) . We also saw a decrease in the mutation rate per base pair for transfer RNA genes (Fig. 2d) , which are hallmarks of selection against potentially deleterious mtDNA variants. Similar patterns have been seen in mice 11, 12 , but the timing and mechanism of the selection was not known. On the basis of our observations, this occurs at an early stage in the developing human female germ line during PGC specification and migration. We were surprised to see some evidence of selection against variants in the non-coding mtDNA D-loop . The arrows show the fluorescent mouse PGCs subsequently isolated by fluorescent sorting. Scale bars, from left to right, 0.5 mm, 1 mm and 0.5 mm. Bottom: fresh human female embryos showing the lower core-body dissected area (outlined in red) for 4-week (Carnegie stage (CS)12) embryos (left), and dissected female embryonic gonads for 5.5-6-week (CS16/17) and 8-week (CS20/21) embryos (middle and right). Scale bars, 1 mm. b, Isolation of human PGCs by fluorescent sorting: for 4-week (CS12) dissected embryos, using a triple-positive combination for TNAP, stage-specific embryonic antigen 4 (SSEA4) and CD38; and for weeks 5-8 (CS16/17 to CS20/21), using gonadal tissue double-positive for TNAP and c-Kit. The boxes in the FACS plots show the sorted cell population. c, The purity of isolated hPGCs was validated by alkaline phosphatase (AP) activity staining showing > 97% positive cells. Scale bars, 100 μ m. See also Fig. 4a-c Each data point represents the mtDNA content in a single cell corresponding to the mean value from the independent qPCR measurements. Source data are available in Supplementary Table 6 . h, MtDNA content of single human embryonic stem cells (hESCs, n = 18), somatic cells (n = 30) and human primordial germ-cell like cells (hPGCLC, n = 48) isolated in vitro 7, 21 . Two independent PGCLC inductions were performed for both the male (WIS2) and female (H9) ESC lines, with cells analysed at day 5/6. Source data are available in Supplementary Table 6 . Each data point represents the mtDNA content in a single cell corresponding to the mean value from the independent qPCR measurements. Horizontal lines in f-h represent the mean values.
NATuRe Cell BIoloGy (Fig. 2d ), but these did not appear to be evenly distributed. CS12 PGCs contained variants in conserved regions not present in CS20/21 PGCs (Fig. 2e) , consistent with selection against variants in regions involved in mtDNA transcription and replication 13 . Given that the majority of the mtDNA variants were present at low heteroplasmy levels (Fig. 2a) , below the conventional threshold required for a biochemical effect, it was not immediately apparent how the selection could occur. To explore the potential mechanism, we measured the absolute amount of mtDNA in the human PGCs at different stages of development in vivo, and then sequenced individual late-stage PGCs to look for evidence of variant segregation. First, we studied human oocytes from three healthy donors, which contained a mean of 1.22 × 10 6 mtDNA molecules (s.d. = 189,742, n = 3) 14 . This was in keeping with previous measurements 15 and confirmed assay reliability. The amount of mtDNA in human PGCs from 14 embryos in vivo was ~1,000-fold less than in oocytes (CS12 mtDNA copies: median 1,425, mean 1,446, s.d. = 77) (Fig. 2f) , consistent with a human genetic bottleneck. The mtDNA levels in female and male PGCs were similar, as previously seen in mice 16 , and resembled new measurements made in Blimp1-mVenus and StellaeCFP [BVSC] mice 17 ( Fig. 2f ; mouse embryonic day (E)9.5 corresponds to human CS12 and mouse E12.5 corresponds to human CS20/21). This validates previous findings in mice with different nuclear genetic backgrounds 16, 18, 19 , and shows a similar mechanism in both humans and mice. However, the lower amount of mtDNA we observed in human PGCs (human/mouse: CS12/E9.5, P < 0.0001; CS16-17/E10.5, P < 0.0001; CS20-21/E12.5, P < 0.0001) predicts a 'tighter' genetic bottleneck in humans than in mice, and thus the more rapid segregation of heteroplasmy. This is in accordance with observations in human and mouse pedigrees where more dramatic shifts in heteroplasmy are seen in humans (see Fig. 4a in ref. 20 ). It is not technically possible to isolate human PGCs from earlier stages because the cells are collected from clinical samples. However, to gain further insight we also measured mtDNA levels in single cells from both the human inner cell mass (ICM) and trophectoderm cells (Fig. 2g) . Although we saw a wide range of mtDNA levels in ICM cells, the mean level (9,794, s.d. = 5,661) was more than fivefold greater than in PGCs. We then studied embryonic stem cells (hESCs) and human PGC-like cells (hPGCLCs) 7, 21 that are derived from the embryonic epiblast in vitro, thus allowing us to estimate the amount of mtDNA at an intermediate stage of human germ cell development ( ) somatic cells isolated from the same in vitro system but not expressing germ-cell markers. These findings suggest a more stringent mtDNA bottleneck in the human female germ line.
Returning to the PGCs isolated in vivo, next we analysed the subcellular distribution of mtDNA molecules within the developing human female germ line. We used the dissector method to measure the number of mitochondria in human PGCs on adjacent-section electron micrographs (Fig. 3a) , validating our results with superresolution whole-cell imaging using Nikon structured illumination microscopy in three dimensions (N-SIM; Supplementary Videos 1 and 2 and Fig. 3b ). The number of mitochondria did not change between CS12 and CS20-21, allowing us to estimate the number of mtDNA per mitochondrion at ~5 per organelle in human PGCs. The reduction in mtDNA content after fertilization of the oocyte (Fig. 2f) , and associated intracellular compartmentalization of mtDNA (Fig. 3a,b) , has important implications for the distribution of mtDNA heteroplasmy between individual organelles. Assuming that mutated mtDNA molecules are randomly distributed between mitochondria, higher levels of heteroplasmy within a cell will be associated with a greater proportion of mitochondria containing very high levels (> 80%) of a specific mutation (Fig. 3c ). For example, if the average level within a cell is 40-50% mutant, then 10-20% of the organelles will contain > 80% mutant mtDNA, exceeding the threshold required to cause a biochemical defect for pathogenic mutations 1, 2 . In this context, ~10-20% of the organelles would be dysfunctional and potentially vulnerable to removal by mitochondrial quality-control mechanisms, removing mutated mtDNA through selection at the organellar level. To determine whether this is plausible, we performed deep mtDNA sequencing on individual late-stage in vivo PGCs (Fig. 3d,e) . This showed much higher percentage levels of mtDNA heteroplasmy within individual germ cells, reaching up to 47% mutant. Thus, following the bottleneck, high levels of mtDNA mutations are found in single PGCs, and are predicted to reach very high levels in individual mitochondria (Fig. 3c) . The most likely explanation for the observed change in codon bias seen between CS12 and CS20-21 (Fig. 2b) is the rapid segregation of variants above and below the assay detection threshold (1% MAF) due to the genetic bottleneck (Fig. 2a,c) , rather than de novo mutation events per se. In this context, even a subtle bias against deleterious variants would tend to suppress them below the detection threshold, whilst allowing non-functional variants to segregate freely to high levels (Fig. 3d) .
To cast light on the possible mechanism of selection, we performed RNA sequencing (RNA-seq) on week-4-9 human PGCs. Unsupervised hierarchical clustering of gene expression and principal component analysis (PCA) of transcriptome confirmed strong expression of germ-cell-specific transcripts (Fig. 4a-c) . Importantly, we also observed a distinct transcript profile for the nuclear-encoded mitochondrial proteins (MitoCarta2.0) 22 in the early stages of PGC development (Fig. 4d) . PCA of both the nuclearencoded and the mtDNA-encoded transcripts showed that the most dramatic changes were during the early stages of germ cell development, with mitochondrial genes forming a cluster distinct from late gonadal PGC genes, such as DAZL and DDX4 ( Supplementary  Fig. 4 ). The mtDNA-encoded transcripts had the highest scores on PC1, accounting for 92% of the total variance (Fig. 4e) . This is consistent with the developmental progression of mtDNA gene expression during PGC development. In contrast, genes involved in the canonical glycolysis pathway had opposing trends on PC1 ( Supplementary Figs. 4 and 5) . Although based solely on transcript analysis, these findings suggest that PGCs become less dependent on glycolytic metabolism and more dependent on oxidative metabolism as they develop. As a consequence, non-synonymous mtDNA mutations are progressively more likely to have phenotypic consequences during germ cell development. The proliferation of PGCs between CS12 and CS20/21 requires considerable mtDNA replication, inevitably introducing new mutations through ϒ polymerase errors. These new mutations are more likely to be synonymous ( Fig. 2) and have no functional consequence. The switch from glycolytic to oxidative metabolism provides an explanation for these findings, by exposing functional variants to the selective effects during this critical time period of PGC development.
Germline mtDNA selection at the organelle level has been proposed in mammals 12, 23 and Drosophila 24, 25 , but it is not known how this occurs. One possibility is that mitochondria depolarize when the proportion of mutated respiratory chain subunits is high, activating intracellular surveillance systems mediated by Pink1 and Parkin, and leading to the selective removal of damaged organelles containing mutant mtDNA by mitophagy 26, 27 . Alternatively, impaired mtDNA replication in ATP-deficient organelles 28 could lead to the preferential turnover of mitochondria containing wildtype genomes; or the transport of mitochondria may be compromised in deficient organelles, preventing their coalescence around 
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the Balbiani body where intense mtDNA replication occurs 18 . In our data, specific genes that were upregulated > 2.5-fold (Fig. 4f) included POLRMT, C10orf2, SLC25A4 and MRPL28, which play a key role in mtDNA replication and gene expression (Supplementary Table 4 ), similarly seen in the PCA (Supplementary Fig. 4) . Thus, mtDNA variants influencing mtDNA replication and expression will also be more likely to have an effect as PGCs develop, providing a possible explanation for the signature of selection we observed against tRNA and D-loop variants between CS12 and CS21 (Fig. 2d,e) .
We also saw low levels of mtDNA somatic cells in vitro (Fig. 2h ) and in vivo (Fig. 5a ), in keeping with a somatic cell bottleneck, as previously observed in mice 19 . We also detected mtDNA variants in the somatic cells in vivo at similar levels to PGCs (Fig. 5b) POU5F1  PRDM14  LIN28A  SOX2  KLF2  KLF4  PRDM1  DND1  CD38  NANOS3  UTF1  ITGB3  KIT  DAZL  DDX4  MAEL  RNF17  PIWIL1  SYCP3  SOX17  GATA4  GATA6  SOX7  HNF4A   GATA2  CD34  HAND1  RUNX1  DCN  WT1  LHX9   15 Only genes with normalized reads counts with (log 2 (normalized counts) > 2.5) were used for analysis. Expression levels were averaged over biological replicates. The number of biological replicates at each developmental stage is shown in the cluster diagram shown in a generated from a total of 13 separate transcriptomes. This shows a progressive change in transcriptome profiles for mitochondrial genes in a sequential manner during PGC development. e, Two-dimensional PCA of RNA-seq gene expression (PC2 against PC1) for mitochondrial nuclear-encoded and mtDNA-encoded genes (MitoCarta2.0) at the different stages of hPGCs (left), with a corresponding plot of the PC scores on PC2 and PC1 (right). Gene names are colour-coded to illustrate upregulated expression in hPGCs.wk9 (purple), and downregulated expression in hPGs.wk9 (red) when compared with the hPGCs.wk4 sample (see also f, Supplementary Figs. 4 and 5 and Supplementary Table 4 ). The arrow line indicates potential mitochondrion-related-transcript progression for each developmental stage from migratory hPGC.w4 to gonadal hPGC.wk9. f, Volcano plot showing differentially expressed genes (from MitoCarta2.0 list) between week 9 (n = 2 independent replicates) and week 4 (this measurement was performed once) hPGCs (log 2 (fold change) > 2.5, P < 0.05, DEseq two-sided; see Methods). See also Supplementary Figs. 4 and 5 and Supplementary Table 4 . Note that the week-9 PGCs included in the RNA-seq analysis were from a slightly later developmental stage than CS20/21, reflecting the clinical samples that were available.
segregation pattern appeared to be different. Some of the mtDNA variants were detected in both the PGCs and the somatic cells from the same embryo, but by the later stages (n = 15 shared variants, CS16-17 and CS20-21), the somatic cells contained higher heteroplasmy levels (P = 0.034, Fig. 5c ). Although based on limited data, this suggests that a less stringent mtDNA bottleneck is present in somatic cells within human embryos, and that mtDNA variants are less constrained by selection in somatic tissues than in the germ line. With rudimentary DNA repair mechanisms and negligible intermolecular recombination, uniparentally inherited genomes have limited means of removing de novo mutations. If left unchecked, the relentless accumulation of mtDNA mutations would eventually lead to 'mutational meltdown' through Muller's ratchet, and extinction of the species 29 . The mtDNA genetic bottleneck has probably evolved to counteract this process, exposing potentially deleterious mutations to selective forces. On the basis of our findings, in humans this occurs early during germline development (Fig. 5d) . However, if a mutation is sufficiently mild to escape germline selection, the same genetic bottleneck can have disastrous consequences. First observed in Holstein cows 30 , dramatic shifts in heteroplasmy levels have been observed within one generation. In humans, healthy mothers harbouring a low-level heteroplasmic mtDNA mutation can have offspring with high levels of heteroplasmy and a severe multisystem disease. Pedigree analyses are consistent with a Variants in the somatic cells had a higher heteroplasmy level than the PGCs (P = 0.03, Fisher's exact test, two-sided), which was not the case at CS12. Source data available are in Supplementary Table 6 . d, In vivo PGCs contain ~300 discrete mitochondria that each contain 5 mtDNA molecules. In vitro data suggest that the amount of mtDNA may be even lower in female germ cells at an earlier stage. Some of the mtDNA molecules are mutated with either neutral (green) or deleterious (red) mutations. Between CS12 and CS20/21, the number of cells increases from ~3000 to ~80,000, accompanied by a massive proliferation of mtDNA molecules within the migrating PGCs. As the mitochondria replicate, the mutations will be copied. The random segregation of mtDNA molecules during mitochondrial fission will generate daughter mitochondria with either high or low levels of the original mutation. If the mutation is deleterious, then it will be selected against. This could be because it compromises ATP synthesis and activates surveillance systems that remove defective mitochondria, or because it compromises mtDNA replication, and thus prevents that particular mitochondrion from being copied. Both of these mechanisms can act in concert at both the cellular and mitochondrial levels.
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NATuRe Cell BIoloGy human mtDNA bottleneck 31 , but there has been no direct evidence in humans. Here we show that a human mtDNA genetic bottleneck exists, and is narrower than the bottleneck in mice 16, 18 (Fig. 2f) . Reducing the amount of mtDNA during this critical time of germ cell development will expose variants to selection acting at the cellular, organellar or mtDNA level, because this coincides with germ cells expressing transcripts for oxidative phorphorylation as they proliferate and migrate to form the gonad. Harnessing the underlying cell biology could help prevent human mtDNA disease, which currently affects ~1 in 11,000. Moreover, given the potential role of mtDNA mutations in common age-related disorders 32 , preventing their transmission may have a wider impact by promoting healthy ageing in future generations.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-017-0017-8.
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Methods
Isolation of single cells. Ethically approved human embryonic tissue samples were provided by the Human Developmental Biology Resource (HDBR), Newcastle University, UK. For CS12 embryos, the lower section (see Fig. 1 ) was dissected in phosphate-buffered saline (PBS) from intact healthy embryos from healthy donors. For CS16 to CS21 embryos, genital ridges from individual embryos were dissected in PBS and the surrounding mesonephric tissue was removed. The dissected tissue was dissociated to a single-cell suspension with 350 μ l in the case of CS12 and 200 and 250 μ l in the case of CS16/7 and CS20/1, respectively, of 5 U ml -1 Liberase DL Research Grade (Roche) at 37 °C for 20-35 min (depending on the stage/size of the tissue). The dissociated sample was then washed with 750-800 μ l of cold Flow Cytometry Staining Buffer (FCSB) (R&D Systems) and the solution was passed through a 50 μ m cell strainer. Twenty microlitres was removed for the cell count using a Tali Image Cytometer (Life Technologies), before the cell suspension was centrifuged at 300g for 5 min at 4 °C. Cells were suspended in cold FCSB and incubated with 5 μ l of Brilliant Violet 421-conjugated antihuman CD38 (Biolegend, 303526), 20 μ l of Alexa Fluor 647-conjugated SSEA-4 (BD Pharmingen, 560796) and 5 μ l of Alexa Fluor 488-conjugated anti-alkaline phosphatase (BD Pharmingen, 561495) in the case of CS12 embryonic tissue, and 5 μ l of Brilliant Violet 421-conjugated anti-human CD117 (c-Kit) (Biolegend, 313216) and 5 μ l of Alexa Fluor 488-conjugated anti-alkaline phosphatase (BD Pharmingen, 561495) in the case of CS16/7 and CS20/1 gonadal tissue for 30 min at 4 °C. Cells were the washed with 1 ml of FCSB and centrifuged at 300g for 5 min at 4 °C. Cells were suspended in fresh cold FACB and sorted using a FACS Aria II (BD Biosciences). To determine the right antibody combination for isolation of pure human PGCs, different cell populations were sorted onto Polysine Microscope Adhesion Slides (Thermo Fisher Scientific) and left to settle in a humidified chamber at room temperature for 20-30 min before being fixed with 4% PFA for 5 min at room temperature. Purity for each sorted population was tested with alkaline phosphatase staining using Leukocyte Alkaline Phosphatase Kit (Sigma-Aldrich). Greater than 97% pure samples were used for downstream analysis. Initially, gender was determined by PCR as described in ref. 33 and then verified by karyotype analysis. Somatic cells were isolated at the same time using the same protocols, and inner cell mass and trophectoderm cells were manually dissected from in vitro-fertilized human day-6 embryos as described previously 34 . In vitro human embryonic stem cells (hESCs), human primordial germ cell-like cells (hPGCLCs) and somatic cells were cultured, induced and isolated as described previously 7, 21 . Two independent PGCLC inductions were performed for both the male (WIS2) and female (H9) ESC lines. Single cells were isolated by FACS using the NANOS3-tdTomato knock-in reporter and the cell surface marker for tissue non-specific alkaline phosphatase (TNAP) in the WIS line, and TNAP/ CD38 double positivity in the h9 line. The somatic cells were isolated during the same FACS sort and were negative for these markers. All cell lines were regularly checked for mycoplasma infection.
The work with the human day-6 embryos was performed under licence from the UK Human Quantification of mtDNA copy number. Quantitative real-time PCR (qPCR) was performed on a CFX96 Touch Real-Time PCR Detection System (BioRad). Human mtDNA copy number was calculated by absolute quantification using a singleplex Taqman assay targeting the mitochondrial MT-ND1 gene (Supplementary Table 1a ). Mouse mitochondrial DNA copy number was calculated by absolute quantification using a singleplex Taqman assay targeting the mitochondrial MT-ND5 gene (Supplementary Table 1b) . Standard curves using PCR-generated templates were used for absolute quantification. Samples and standards were measured in triplicate.
Somatic cells, human inner cell mass, trophectoderm, human embryonic stem cells, human primordial germ cell-like cells, and in vitro somatic cells.
MtDNA levels were measured using the same protocols as for the PGCs.
Immunocytochemistry. PGCs were sorted on Polysine Microscope Adhesion Slides (Thermo Fisher Scientific) and left to settle in a humidified chamber at room temperature for 20-30 min before fixation with 4% PFA for 10 min at room temperature, washed three times with PBS, 0.1% Tween-20, (5 min each wash) and incubated for 20 min with PBS, 0.3% Triton-X buffer, and washed three times with PBS, 0.1% Tween-20 (5 min each wash). Cells were subsequently blocked for 1 h with PBS, 2.5% BSA, 0.1% Tween-20 and 5% normal goat serum at room temperature followed by staining with DDX4 (VASA) mouse monoclonal IgG1 antibody (Selleckchem) diluted 1:200 in the blocking solution at 4 °C overnight. The slides were then washed three times with PBS, 0.1% Tween-20 (5 min each wash) and incubated with Alexa fluorophore-conjugated secondary antibody (Molecular Probes) 1:500 diluted in PBS, 0.1% Tween-20 for 1 h at room temperature in the dark, washed three times in PBS, 0.1% Tween-20 (5 min each wash) and once in PBS for 5 min. Finally, the glass-bottom dishes were mounted in ProLong Gold Antifade Mountant with DAPI (Molecular Probes) and imaged using a Zeiss Axio Imager Z1/Apotome Microscope.
Electron microscopy. PGCs were collected in 1.5 ml microcentrifuge tubes containing 2.5% electron-microscopy-grade glutaraldehyde (TAAB Laboratories Equipment) in Sorenson's phosphate buffer 0.2 M pH 7.4 (Electron Microscopy Sciences) and stored at 4 °C overnight. The cells were enrobed in low-meltingpoint agarose (4%) to form a small block. After secondary fixation in 2% osmium tetroxide (Agar Scientific), the cells were dehydrated in graded acetone, embedded in epoxy resin (TAAB) and polymerized at 60 °C. Semi-thin sections (0.5 µ m) were taken from the resin block and stained with toluidine blue to identify the first cells. As soon as cells were found in the block, ultrathin serial sections (70 nm) were taken and collected on copper washer grids (Gilder Grids). Serial sections were taken for approximately 150 µ m to ensure that there would be at least 6 whole cells sectioned. The grids were stained with uranyl acetate and lead citrate (Leica UK) and viewed on a Philips CM100 TEM (FEI). Cells that were completely sectioned were imaged from each sample and mitochondria counted using the dissector technique 35 . Pairs of images 140 nm apart were taken at several levels through each cell. Each pair is comprised of a 'reference' and 'look-up' section. The number of mitochondria that are hit by the reference section but not by the look-up section is counted. To increase efficiency, the roles of the reference and look-up sections can be reversed. If the volume of the dissector is known, then the number density Nv can be obtained. The volume of the dissector equals the area of cell profile multiplied by the distance between the paired sections. Multiplying number density by cell volume gives mitochondrial number.
Super-resolution microscopy. PGCs were collected in 35-mm-diameter glassbottom dishes (glass no. 1.5, 0.170 ± 0.005 mm, high-tolerance coverslip; MatTek) and left to settle in a humidified chamber at room temperature for 20-30 min before being fixed with 4% PFA for 10 min at room temperature. Dishes were washed three times with TBS (pH 7.6), 0.1% Tween-20 (5 min each wash) and then permeabilized for 10 min using TBS, 0.1% sodium citrate, 0.2% Triton-X buffer, before being washed three times with TBS, 0.1% Tween-20 (5 min each wash). Cells were subsequently blocked for 1 h with TBS, 0.3 M glycine, 2.5% BSA, 5% normal goat serum, 0.1% Tween-20 buffer at room temperature followed by staining with TOM20 mouse monoclonal IgG2a antibody (F-10), sc-17764 (Santa Cruz Biotechnology) diluted 1:1,000 in the blocking solution at 4 ˚C overnight. The glass-bottom dishes were then washed three times with TBS, 0.1% Tween-20 (5 min each wash) and incubated with Alexa fluorophore-conjugated secondary antibody (Molecular Probes) 1:1,000 diluted in TBS, 0.1% Tween-20 for 1 h at room temperature in the dark, washed three times in PBS, 0.1% Tween-20 (5 min each wash) and once in TBS for 5 min. Finally, the glass-bottom dishes were mounted in ProLong Gold Antifade Mountant with DAPI (Molecular Probes) and imaged using a Nikon Structured Illumination Microscope.
Image segmentation analysis for measuring mitochondrion content. Threedimensional reconstruction of super-resolution z-stack images was rendered using NIS-Elements software (Nikon). Mitochondrion content count and visualization of PGCs were performed using Imaris software (Bitplane).
Ultradeep sequencing and variant analysis. Details of collected samples are given in Supplementary Table 2 . PGCs and somatic cells were sorted and lysed in 96-well plates as described above and mtDNA was amplified using PrimeSTAR GXL DNA polymerase (error rate = 0.00108%, Takara Bio) in nine overlapping fragments (Supplementary Table 1c ) for grouped cells or in two overlapping fragments (Supplementary Table 1d ) for the single cells. The specificity of mtDNA amplification was assessed using DNA extracted from Rho0 cell lines previously shown to be devoid of mtDNA 4 . There was no template amplification after > 40 PCR cycles, confirming that the primers amplified only mtDNA and not nuclear-mitochondrial sequences. No PCR products were generated with any of the primers. Amplified products were assessed by gel electrophoresis, against DNA-positive and DNA-negative controls. Each amplicon was individually purified using Agencourt AMPure XP beads (Beckman-Coulter), quantified using a Qubit 2.0 fluorimeter (Life Technologies) and amplicons from the same sample were pooled. Libraries were prepared for Next Generation Sequencing (NGS) using the Illumina Nextera XT DNA sample preparation kit (Illumina), and pooled amplicons were 'tagmented' , amplified, cleaned, normalized and pooled 1 nature research | life sciences reporting summary Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design
Sample size
Describe how sample size was determined. This was an observational study. Samples sizes were chosen based on the human tissue available. All available tissue was analysed. No statistical methods were used to determine the sample size.
Data exclusions
Describe any data exclusions. None
Replication
Describe whether the experimental findings were reliably reproduced.
Repeat biological and technical replicates validated our findings
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization process was employed
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Data were analysed by a bioinformatician blind to the origin/category of the samples Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
